Results 11 to 20 of about 36,269 (231)

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Clinical Cancer Research, 2023
Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible inhibitor, futibatinib.
Qibiao Wu, H. Ellis, Giulia Siravegna, Alexa G Michel, B. Norden, F. Fece de la Cruz, E. Balasooriya, Y. Zhen, V. S. Silveira, Jianwei Che, R. Corcoran, N. Bardeesy   +11 more
semanticscholar   +1 more source

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas

Cell & Bioscience, 2023
Background Except for gene fusions, FGFR2 genetic alterations in intrahepatic cholangiocarcinomas (ICCs) have received limited attention, leaving patients harboring activating FGFR2 gene mutations with inadequate access to targeted therapies ...
Xiaohong Pu, Liang Qi, Jia Wu Yan, Zihe Ai, Ping Wu, Fei Yang, Yao Fu, Xing Li, Min Zhang, Beicheng Sun, Shen Yue, Jun Chen   +11 more
doaj   +1 more source

CRISPR/Cas9 mediated FGFR2 down-regulation alleviatespremature closure of cranial suture in an Apert syndromemouse model

生物医学转化, 2021
Apert syndrome (AS) is characterized by synostosis of coronal sutures, midfacial hypoplasia,abnormity of brain, syndactyly of hands and feet. Majority of AS is caused by gain-of-function mutation of fibro‐blast growth factor receptor 2 (FGFR2).
Luo Fengtao, Xie Yangli, Li Can, Tan Qiaoyan, Du Xiaolan, Chen Lin   +5 more
doaj   +1 more source

OTUB1 promotes osteoblastic bone formation through stabilizing FGFR2

Signal Transduction and Targeted Therapy, 2023
Bone homeostasis is maintained by the balance between osteoblastic bone formation and osteoclastic bone resorption. Dysregulation of this process leads to multiple diseases, including osteoporosis.
Qiong Zhu, Yesheng Fu, C. Cui, Yiyao Ding, Zhikang Deng, Chao Ning, Fan Hu, Chen Qiu, Biyue Yu, Xu Zhou, Guan Yang, Jiang Peng, Weiguo Zou, C. Liu, Lingqiang Zhang   +14 more
semanticscholar   +1 more source

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy

Advanced Science, 2021
Fibroblast growth factor receptor 2 (FGFR2) is a membrane‐spanning tyrosine kinase that mediates FGF signaling. Various FGFR2 alterations are detected in breast cancer, yet it remains unclear if activation of FGFR2 signaling initiates tumor formation. In
Josh Haipeng Lei, Mi‐Hye Lee, Kai Miao, Zebin Huang, Zhicheng Yao, Aiping Zhang, Jun Xu, Ming Zhao, Zenan Huang, Xin Zhang, Si Chen, NG Jiaying, Yuzhao Feng, Fuqiang Xing, Ping Chen, Heng Sun, Qiang Chen, Tingxiu Xiang, Lin Chen, Xiaoling Xu, Chu‐Xia Deng   +20 more
doaj   +1 more source

FGFR2 modulates the Akt/Nrf2/ARE signaling pathway to improve angiotensin II-induced hypertension-related endothelial dysfunction

Clinical and Experimental Hypertension, 2023
Background Fibroblast growth factor receptor (FGFR)2 expression was decreased in hypertension patients while its role in hypertension was not explored. This experiment aimed to investigate the expression ofFGFR2 in angiotensin II (Ang II)-induced human ...
Kun Jiao, Ping Su, Yongling Li
doaj   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways

Clinical and Translational Medicine, 2023
Background Mutations in the receptor tyrosine kinase gene fibroblast growth factor receptor 2 (FGFR2) occur at a high frequency in endometrial cancer (EC) and have been linked to advanced and recurrent disease.
G. Dixit, J. Gonzalez-Bosquet, Joseph Skurski, E. Devor, E. Dickerson, W. Nothnick, Priya D. Issuree, K. Leslie, Thorsten Maretzky   +8 more
semanticscholar   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

FGFR2 upregulates PAI-1 via JAK2/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer.

Biochimica et Biophysica Acta - Molecular Basis of Disease, 2023
Fibroblast growth factor receptor 2 (FGFR2) is frequently activated by overexpression or mutation, and an abnormal fibroblast growth factor (FGF)/FGFR signaling pathway is associated with the occurrence, development, and poor prognosis of colorectal ...
Yiming Li, Yongkang Shi, Xiuyuan Zhang, Piao-Piao Li, Li Ma, Peng Hu, Liang Xu, Yuhong Dai, Shu Xia, H. Qiu   +9 more
semanticscholar   +1 more source